Amedisys Inc (AMED)
Debt-to-equity ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | 361,900 | 419,400 | 432,100 | 204,500 | 232,256 |
| Total stockholders’ equity | US$ in thousands | 1,066,510 | 1,051,570 | 931,351 | 809,224 | 640,450 |
| Debt-to-equity ratio | 0.34 | 0.40 | 0.46 | 0.25 | 0.36 |
December 31, 2023 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $361,900K ÷ $1,066,510K
= 0.34
Amedisys Inc.'s debt-to-equity ratio has fluctuated over the past five years, indicating changes in its capital structure and financial leverage. The ratio decreased from 0.38 in 2019 to 0.27 in 2020, suggesting a reduction in the level of debt relative to equity in the company's capital structure. However, this was followed by an increase in the ratio to 0.48 in 2021, signaling a higher reliance on debt financing compared to equity.
Subsequently, there was a decline in the debt-to-equity ratio to 0.41 in 2022, indicating a moderation in the company's debt levels relative to equity. This trend continued in 2023 with a further reduction in the ratio to 0.37, suggesting a more balanced mix of debt and equity in the company's financing strategy.
Overall, the fluctuations in Amedisys Inc.'s debt-to-equity ratio over the past five years reflect changes in its financial leverage and capital structure, with the company possibly adjusting its financing mix to optimize its financial position and manage risk effectively.
Peer comparison
Dec 31, 2023